Gilead Sciences Inc.: clinical-trial pipeline
Gilead Sciences Inc. is the sponsor of 684 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 74 are not yet finished and 4 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials74
Phase 2/3 and 3211
Countries60
New in 90 days4
Trials by phase
| Phase | Trials |
|---|---|
| Phase 2 | 220 |
| Phase 3 | 192 |
| Phase 1 | 132 |
| Not applicable | 45 |
| Phase 1/2 | 40 |
| Phase 4 | 36 |
| Phase 2/3 | 19 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 465 |
| Terminated | 122 |
| Active, not recruiting | 42 |
| Recruiting | 22 |
| Withdrawn or not authorised | 16 |
| Not yet recruiting | 10 |
| Unknown | 7 |
Condition areas
| Area | Trials |
|---|---|
| Infectious disease and vaccines | 381 |
| Gastroenterology and liver | 223 |
| Oncology | 150 |
| Rare and genetic diseases | 67 |
| Respiratory | 62 |
| Cardiovascular | 44 |
| Immunology and rheumatology | 40 |
| Metabolic and endocrine (diabetes, obesity) | 27 |
| Nephrology and urology | 11 |
| Haematology | 9 |
| Women's health and obstetrics | 5 |
| Dermatology | 4 |
Countries
| Country | Trials |
|---|---|
| United States | 523 |
| United Kingdom | 191 |
| Canada | 180 |
| France | 178 |
| Germany | 171 |
| Spain | 161 |
| Italy | 148 |
| Australia | 142 |
| Puerto Rico | 103 |
| Belgium | 99 |
| New Zealand | 88 |
| Poland | 87 |
| South Korea | 72 |
| Austria | 63 |
| Netherlands | 62 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-09-25 | New trial posted | Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis |
| 2026-09-25 | New trial posted | Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1… |
| 2026-09-08 | New trial posted | Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Ce… |
| 2026-09-07 | New trial posted | Study of GS-2426 in Participants With Advanced Solid Tumors |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT05089734 | Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Ce… | Phase 3 | Active, not recruiting | Austria, Australia, Belgium, Brazil +15 |
| NCT06333808 | Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Tre… | Phase 3 | Not yet recruiting | Argentina, Australia, Canada, Germany +11 |
| NCT03964727 | Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors | Phase 2 | Active, not recruiting | Australia, Belgium, Canada, Spain +4 |
| NCT03301506 | Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC) | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Belgium +20 |
| NCT05186974 | Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastat… | Phase 2 | Active, not recruiting | Australia, Canada, Germany, Spain +8 |
| 2023-509825-38-00 | A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemoth… | Phase 3 | Active, not recruiting | Austria, Belgium, Germany, Spain +4 |
| NCT06290934 | Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis | Phase 2 | Not yet recruiting | Austria, Australia, Belgium, Canada +18 |
| NCT06303505 | FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adeno… | Phase 1/2 | Recruiting | Belgium, Germany, Spain, United Kingdom +4 |
| NCT06513312 | Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP) | Phase 2 | Active, not recruiting | France, United Kingdom |
| NCT06532656 | Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1 | Phase 2/3 | Active, not recruiting | Argentina, Spain, Italy, United States +1 |
| NCT05633654 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With… | Phase 3 | Recruiting | Australia, Belgium, Brazil, Germany +8 |
| NCT05382299 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untrea… | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Belgium +25 |
| NCT05382286 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizuma… | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Belgium +23 |
| NCT01651403 | Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Pla… | Phase 3 | Active, not recruiting | India, South Korea, Romania, Taiwan +1 |
| NCT06630286 | Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafe… | Phase 3 | Active, not recruiting | Argentina, Australia, Canada, Switzerland +8 |
| NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer… | Phase 3 | Active, not recruiting | Australia, Brazil, Canada, China +15 |
| NCT06727565 | Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Reg… | Phase 2 | Active, not recruiting | Australia, China, Spain, France +5 |
| NCT06630299 | Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppres… | Phase 3 | Active, not recruiting | Argentina, Australia, Switzerland, Germany +10 |
| NCT06544733 | Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Bik… | Phase 2/3 | Active, not recruiting | Germany, Spain, France, Italy +4 |
| NCT06801834 | Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stag… | Phase 3 | Recruiting | Argentina, Australia, Belgium, Brazil +19 |
| NCT06051617 | Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | Phase 3 | Recruiting | Argentina, Austria, Australia, Belgium +24 |
| NCT06902519 | Study of GS-0151 in Participants With Rheumatoid Arthritis | Phase 1 | Active, not recruiting | Germany, Spain, Georgia, Moldova +2 |
| NCT06657222 | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | Phase 1/2 | Not yet recruiting | Canada, Spain, France, Romania +1 |
| NCT07128303 | Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors | Phase 1 | Recruiting | Spain, South Korea, United States |
| NCT07736937 | Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer | Phase 1/2 | Recruiting | Belgium, Ukraine, United States |
Hiring for clinical development
Gilead Sciences Inc. has 136 open jobs with a clinical, regulatory, safety, biostatistics or medical-affairs title on its own career sites.
Website: gilead.com. All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Gilead Sciences Inc. clinical trials: 74 open, 211 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/gilead-com/, data as of 2026-10-25.